While R&D costs rise and productivity falls, the pressure to achieve return on investment for new innovative drugs is higher than ever before. Therefore, together with BIOCOM, we are organising a webinar on "How to accelerate drug development and reduce costs with in-human data before Phase I".
Why join? The webinar will teach you how to make use of a so called microdosing strategy to accelerate the development of your drug(s). The FDA approved microdosing concept shows whether a tested compound reaches the target tissue in humans. This data is gathered before Phase I. By employing a microdosing strategy a drug developer gains many advantages, such as:
- Make early go/no-go decisions on MNEs
- Skip costly large animal toxicity studies by having in-human data
- Monitor progression of diseases or results of treatment over time
- Boost company valuations with positive in-human data even before Phase I
Already want to know more about in-human microdosing and what it can do for your drug development process? We wrote a blog about the FDA approved concept of microdosing. A great introduction to our webinar.
For this webinar please register through the BIOCOM link to claim your spot.
Date: June 23, 2020
Time: 9am-10.30am (PDT) or 6pm-7.30pm (CEST)